Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $57.8571.
Several equities research analysts recently commented on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a research report on Monday. Zacks Research cut Omnicell from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Piper Sandler reissued an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research report on Wednesday, April 29th.
View Our Latest Research Report on Omnicell
Hedge Funds Weigh In On Omnicell
Omnicell Stock Performance
Shares of OMCL stock opened at $33.22 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The company has a market capitalization of $1.51 billion, a P/E ratio of 39.55, a price-to-earnings-growth ratio of 0.87 and a beta of 0.98. The company’s 50 day moving average price is $40.14 and its two-hundred day moving average price is $39.44. Omnicell has a 52 week low of $29.06 and a 52 week high of $55.00.
Omnicell (NASDAQ:OMCL – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. During the same quarter in the previous year, the firm posted $0.45 earnings per share. The business’s revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, analysts expect that Omnicell will post 1.41 earnings per share for the current fiscal year.
Omnicell Company Profile
Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.
Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.
See Also
- Five stocks we like better than Omnicell
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
